NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Clinical Trials
23 trialsNCT05456191 2026-02-06
ASC4START
Novartis
Phase 3 Active not recruiting
NCT03784014 2025-12-11
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Active not recruiting
NCT02201459 2025-10-02
PETALs
Hospices Civils de Lyon
Phase 3 Completed
NCT02326311 2024-08-13
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 3 Completed
NCT01657604 2023-05-10
TIGER
University of Jena
Phase 3 Completed
NCT03942094 2022-03-16
Nilotinib for First-line Newly Diagnosed CML-CP Patients
Shenzhen Second People's Hospital
Phase 3 Unknown
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT02115386 2019-12-10
MACS1532
Novartis
Phase 3 Terminated
NCT02174445 2019-12-02
DECLINE
University Hospital Freiburg
Phase 3 Terminated
NCT02272777 2019-08-19
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Novartis
Phase 3 Completed
NCT03079505 2019-01-23
DANIN
Hamad Medical Corporation
Phase 3 Terminated
NCT01535391 2018-08-06
CML0811
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Completed
NCT01126892 2017-02-28
ENACT
Novartis
Phase 3 Completed
NCT01289028 2017-01-02
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
Novartis
Phase 3 Completed
NCT00760877 2016-11-08
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
Novartis
Phase 3 Completed
NCT01275196 2016-04-08
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
Novartis
Phase 3 Completed
NCT01254188 2016-03-03
ENESTxtnd
Novartis
Phase 3 Completed
NCT00802841 2015-11-16
LASOR
Novartis
Phase 3 Completed
NCT00751036 2014-03-26
MACS0375
Novartis
Phase 3 Terminated
NCT01400074 2014-01-13
RE-NICE
Seoul St. Mary's Hospital
Phase 3 Unknown
NCT01819389 2014-01-07
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
Hospital Universitario Dr. Jose E. Gonzalez
Phase 3 Completed
NCT00471328 2012-06-12
ENEST
Novartis
Phase 3 Completed